17-deoxycortisol
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2010 (NCT01079455)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cytochrome P450 17A1INHIBITOR
CYP17A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 11beta,21-dihydroxy-4-pregnene-3,20-dione
- 11beta,21-dihydroxy-4-pregnene-3,20-dione
- (11β)-11,21-dihydroxypregn-4-ene-3,20-dione
- (11β)-11,21-dihydroxypregn-4-ene-3,20-dione
- 11β,21-dihydroxyprogesterone
- 11β,21-dihydroxyprogesterone
- 17-deoxycortisol
- 17-deoxycortisol
- corticosterone
- corticosterone
- corticosterone
- kendall's compound b
- kendall's compound b
- reichstein's substance h
- reichstein's substance h
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01079455 | Phase 3 | May 1, 2010 | University Hospital Pellenberg |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University Hospital Pellenberg | Academic/Hospital | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1